Author: R&D Team, CUIGUAI Flavoring
Published by: Guangdong Unique Flavor Co., Ltd.
Last Updated: Sep 07, 2026
WhatsApp & Telegram: +86 189 2926 7983
Email: info@cuiguai.com
Australian TGA TGO 110 Compliance E-Liquids
Answer first: Australia is pharmacy-only, but it is no longer accurate to call the whole system “prescription-only.” Since 1 October 2024, an adult aged 18 or over may obtain a therapeutic vape containing 20 mg/mL nicotine or less from a participating pharmacy without a prescription when the pharmacist judges supply clinically appropriate and applicable state or territory law allows it. A prescription remains required for people under 18 and for nicotine concentrations above 20 mg/mL, as well as in some jurisdictional or clinical circumstances. [1][2]
The commercial framework is tightly controlled. From 1 July 2024, all vapes—including nicotine-free goods—may be sold only through participating pharmacies for smoking cessation or management of nicotine dependence. Disposable single-use and non-therapeutic vapes are prohibited. Therapeutic flavors are restricted to mint, menthol and tobacco, while an unflavored formulation contains no flavor. Products must satisfy the current TGA standards and sponsor-notification pathway; pharmacy supply does not mean the TGA has evaluated each notified product for safety, quality, efficacy or performance. [1][2]
For formulators, search intent should begin with the regulatory decision tree rather than a flavor concept: Is the product therapeutic? Is it reusable? Who is the Australian sponsor? Is the nicotine concentration within the product maximum and the chosen supply schedule? Are every ingredient, device component, label and package compliant with the strengthened standards fully applicable from 1 July 2025? Only after those questions are answered should sensory optimization begin.
Understanding the shift from consumer to clinical standards is crucial. To contextualize how strict ingredient prohibitions govern global formulation strategies, review our comprehensive analysis on EU TPD Compliance: The Forbidden Ingredients List.
Access — Participating pharmacies are the only retail channel. Adults 18+ may receive products at 20 mg/mL nicotine or less without a prescription after pharmacist consultation where local law allows. Higher concentrations and under-18 supply require a prescription. [1][2]
Product — Non-therapeutic and disposable single-use vapes are prohibited. From 1 July 2025, supplied unapproved therapeutic vapes must meet the strengthened standards. TGO 110 caps nicotine at 50 mg/mL, menthol at 20 mg/mL, containers at 60 mL and substance accessories at 5 mL. [3]
Flavor and presentation — Finished therapeutic vapes may be unflavored or use the permitted mint, menthol or tobacco categories, subject to the permitted-ingredient rules. Labels and packs are predominantly white, use limited colors and must avoid promotional, food, drink, cosmetic or health-benefit cues. [3]
Regulatory status — There are currently no smoking-cessation or nicotine-dependence vapes in the ARTG, according to TGA pharmacist guidance. Notified unapproved goods have not been assessed by TGA for quality, safety, efficacy or performance. Never say “TGA approved” merely because a product appears on the notified list. [2]
The Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Act 2024 commenced on 1 July 2024. It prohibits importation, domestic manufacture, supply, commercial possession and advertising of disposable single-use and non-therapeutic vapes. It does not ban every vape: compliant therapeutic vaping goods for smoking cessation or management of nicotine dependence may be supplied through participating pharmacies under federal and state or territory requirements. [1]
From 1 October 2024, adults aged 18 and over may receive nicotine at 20 mg/mL or less from a participating pharmacist without a prescription where clinically appropriate and legally permitted locally. The pharmacist must verify identity and age, obtain informed consent, discuss registered alternatives and appropriate use, limit supply to no more than one month in a month, and make the required SAS-C notification. A prescription is required above 20 mg/mL and for people under 18, subject to jurisdictional law. Pharmacists cannot be compelled to stock or supply a product. [2]
The operative product standard is the Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021 as amended, commonly described in TGA guidance as TGO 110 (2024). Strengthened requirements took effect for import/manufacture from 1 March 2025 and for lawful supply from 1 July 2025. The updated standard uses permitted-ingredient controls rather than the article’s former unsupported shorthand list of “prohibited ingredients.” Sponsors and manufacturers must check the current instrument and schedules for every constituent and applicable limit. [3][4]
The strengthened standard caps nicotine at 50 mg/mL expressed as nicotine base or equivalent base-form concentration, caps menthol at 20 mg/mL, limits vaping-substance containers to 60 mL and substance accessories to 5 mL, and imposes plain-pack, label and information-leaflet rules. Device and accessory requirements sit under the separate Medical Device Standard Order (MDSO), including technical, battery, quality-system, risk-management and toxicological-risk-assessment obligations. Do not state that a particular aerosol-emissions protocol is universally mandated unless the current instrument, sponsor pathway or device assessment requires it.
Pharmaceutical E-Liquid Flavor Testing Laboratory
Australia restricts therapeutic vape flavors to mint, menthol and tobacco; unflavored products contain no flavor. TGA label guidance states that a flavored product’s ingredient list must use the word “flavour” preceded by “menthol,” “mint” or “tobacco/classic.” The rule applies to the finished therapeutic vaping substance, not merely the front-of-pack name. A fantasy name or a tobacco label cannot cure a formula that contains a non-permitted ingredient or presents as another flavor. [3]
The finished product should be evaluated as a whole: formula, ingredient function, concentration, sensory character, name, graphics, claims and information leaflet. TGO 110 packaging must be predominantly white, use limited colors and avoid food, drink, cosmetic, health-benefit or promotional cues. This means a “mint” product should not be presented as confectionery, and a “tobacco” product should not be named or illustrated like dessert. The legal test is not satisfied by deleting a flavor word from the label.
A compliant formulation begins with the current permitted-ingredient list and concentration conditions in TGO 110, followed by supplier evidence for identity, grade, impurities and batch consistency. Traditional RY4-style concepts may contain caramel, vanilla or confectionery signals that conflict with the permitted flavor categories or ingredient list. Each constituent must be assessed individually; “used at trace level” is not an exemption.
Do not assume that every pyrazine, phenol, terpene, sweetener or cooling agent is permitted simply because it can create a tobacco or mint impression. Regulatory category and toxicological suitability are separate questions. The sponsor’s bill of materials should map every CAS number, function, concentration, specification and supplier to the relevant TGO permission, with a controlled rationale for any processing aid or impurity.
As the industry moves away from complex dessert profiles due to regulatory pressure, understanding the chemical mechanisms of flavor modification remains valuable. Explore our analysis on Customization Trends: The Return of Flavor Shots to see how isolated flavor compounds perform.
Natural tobacco extracts may introduce variable alkaloids, tobacco-specific nitrosamines, pesticides, metals, residual solvents and batch-to-batch sensory variation. Synthetic tobacco-style compositions can improve control but are not automatically lawful or risk-free. The correct choice is the one whose individual ingredients are permitted and whose identity, purity, concentration, impurities and stability are supported by the sponsor’s quality dossier.
Avoid absolute claims such as “zero risk of TSNA contamination” or “guaranteed compliance.” Analytical methods have detection limits, supply chains change and the finished formulation—not an ingredient marketing sheet—is regulated. A stronger statement is evidence-based: define acceptance limits, validate or qualify the method, report results with the limit of quantification, and investigate trends across batches.
To secure highly purified, synthetically constructed profiles that guarantee compliance without sacrificing sensory authenticity, explore our specialized Tobacco flavor concentrates designed for highly regulated markets.
Sensory optimization must remain inside the permitted formula. PG/VG ratio, nicotine form, device power and aerosol temperature can change throat sensation and flavor delivery, but they also affect performance and risk. Any adjustment should pass compatibility, dose-delivery and stability review. Do not infer that a sweetener is lawful or unlawful from its sensory effect alone; verify it against the current TGO schedule.
Pharmaceutical Mint and Menthol Ingredients for E-Liquids
Mint and menthol are permitted flavor categories for a compliant therapeutic vaping substance. Menthol can alter cooling and throat sensation, but product claims should stay within the authorized therapeutic context. A pharmacy product is not an invitation to promote refreshment, lifestyle or recreational appeal.
TGO 110’s current maximum menthol concentration is 20 mg/mL. Supplier pharmacopoeial claims can support quality where relevant, but the former statement that Australian law universally requires USP/EP L-menthol above 99.5% was too specific and has been removed. The sponsor should set an evidence-based grade and impurity profile, verify identity and assay, and ensure every ingredient and concentration is permitted under the current standard. [3]
A mint label cannot disguise a candy or gum proposition. Packaging and product names must not suggest food or drink or increase appeal to youth or recreational users. Formula review should consider both permitted ingredients and the overall sensory result. Sweeteners or vanilla-type modifiers should not be described as categorically banned without checking the current schedule, but they may create both ingredient and presentation problems.
For a highly stable, non-sweetened cooling sensation that strictly adheres to the botanical boundaries required by pharmacy regulations, evaluate our premium Cool flavor formulations, leveraging high-purity molecular coolants.
Therapeutic vaping goods are regulated under the Therapeutic Goods Act framework, but requirements vary by product, manufacturing activity and pathway. Avoid the blanket claim that every overseas flavor concentrate factory must hold a particular Australian GMP certificate. The Australian sponsor remains responsible for ensuring the finished unapproved therapeutic vape complies with TGO 110, sponsor-notification, import/manufacture, supply and recordkeeping obligations.
A defensible supply system includes approved suppliers, material specifications, identity testing, batch records, traceability, deviation and change control, cleaning validation where relevant, complaint handling, stability support and recall cooperation. “Sterility” should not be promised unless the product is required and validated to be sterile. TGO 100 microbiological standards also apply to unapproved therapeutic vapes as described in TGA guidance. [3]
Use a quality agreement between sponsor, finished-product manufacturer and critical suppliers. It should cover formula disclosure under confidentiality, prohibited substitutions, notification before changes, audit rights, investigations, retention samples, data integrity and regulatory cooperation. Proprietary information can be protected by contract, but the sponsor still needs enough detail to demonstrate compliance.
GMP Certified E-Liquid Flavor Manufacturing Facility
A sponsor-ready dossier should contain: full qualitative and quantitative composition; ingredient names and identifiers; function and TGO permission mapping; raw-material and finished-product specifications; representative COAs; analytical methods and detection limits; impurity and contaminant rationale; stability and packaging-compatibility data; change-control history; allergen and sensitization review; SDS where applicable; and contact details for rapid investigation. The dossier should distinguish supplier data from tests on the finished product.
The Australian sponsor must submit a notice before importing or supplying an unapproved therapeutic vape and ensure that goods sourced by pharmacies are on the notified vape list or otherwise included in the ARTG. The notified list is not a TGA approval: TGA states that listed unapproved vapes have not been assessed for quality, safety, efficacy or performance. Marketing should never convert notification into an “approved by TGA” claim. [2][3]
Australia’s climate and long shipping routes justify careful stability planning, but TGO compliance does not automatically require every flavor concentrate to travel in a 15–20°C refrigerated container. Define shipping and storage conditions from formulation-specific stability, container-closure compatibility and excursion studies. Identify light-, oxygen- and heat-sensitive constituents, then select a packaging and monitoring plan proportionate to the demonstrated risk.
Possible controls include light-resistant compatible containers, minimized headspace, tamper evidence, insulated freight, temperature indicators or data loggers. Nitrogen blanketing or refrigerated freight should be used only where validated and operationally controlled. The receiving party needs acceptance criteria for excursions, quarantine procedures and access to the supporting stability assessment.
Consumer language such as “steeping” is unsuitable for a controlled therapeutic supply chain. Define manufacturing hold times, mixing endpoints and release timing in approved instructions. Establish a shelf life from a written stability protocol covering relevant chemical, physical, microbiological, packaging and performance attributes. The former claim that TGA universally requires six-to-twelve-month testing has been removed.
Trend nicotine assay and degradation, pH where relevant, flavor-marker or impurity results, appearance, leakage, container interaction and device compatibility over the proposed shelf life. Use stability-indicating methods where necessary. A change in flavor supplier, composition, grade, container, device or process should trigger documented impact assessment and any required sponsor update before release.
Yes, a product can contain no flavor, provided the formulation and finished good meet all applicable requirements. Do not describe it as “TGA approved”; lawful supply of an unapproved notified vape is different from ARTG evaluation.
Do not decide from flavor name alone. Check whether sucralose is a permitted ingredient under the current TGO 110 schedule and whether the overall formula, name and presentation remain within the permitted tobacco category. If either test fails, the product is non-compliant.
Provide full qualitative and quantitative composition under appropriate confidentiality, ingredient identifiers and TGO mapping, specifications, representative COAs, methods and limits, impurity data, stability and compatibility support, batch traceability, SDS where applicable, and formal change-notification commitments. The Australian sponsor determines what additional evidence the finished product requires.
Do not assume WS-23, WS-3 or any other synthetic coolant is allowed because the finished sensation seems “mint.” Each chemical must appear within the current permitted-ingredient framework at an allowed concentration, and the finished product must comply with flavor, naming and presentation rules.
TGO guidance recognizes tobacco/classic as a permitted flavor label. Compliance depends on the permitted ingredients and the finished product’s formula, name and presentation. There is no safe shortcut based on a subjective claim that a blend “tastes like tobacco.”
No. Disposable single-use vapes are prohibited regardless of nicotine content or flavor. Compliant therapeutic reusable goods may be supplied only through the regulated pharmacy pathway. [1]
Avoid a universal statement that every upstream flavor site must hold one named certification. The sponsor must ensure the finished therapeutic vape and its supply chain satisfy applicable TGA standards and quality obligations. Supplier qualification and robust quality records remain essential even where a specific GMP licence is not imposed on the flavor supplier.
Only if every constituent is permitted and the sponsor can control the extract’s variability and contaminants. Natural extracts can present alkaloid, TSNA, pesticide, metal and residual-solvent questions. A product-specific analytical and toxicological assessment is required; “natural” is not a compliance category.
No. Since 1 October 2024, adults aged 18 or over may obtain 20 mg/mL nicotine or less from a participating pharmacy without a prescription when clinically appropriate and permitted by state or territory law. A prescription is required above 20 mg/mL and for people under 18. [1][2]
No. TGA states that notified unapproved products have not been assessed for quality, safety, efficacy or performance. Notification supports a lawful pathway but is not ARTG registration or approval. [2][3]
Are you preparing a mint, menthol, tobacco or unflavored formulation for Australia’s pharmacy-only pathway? Contact CUIGUAI to discuss composition disclosure, specifications and change control. The Australian sponsor remains responsible for TGO 110, MDSO, notification, import and supply compliance.
📞 Phone: +86 0769 8838 0789
🌐 Website: https://www.cuiguai.com
📧 Email: info@cuiguai.com
💬 WhatsApp & Telegram: +86 189 2926 7983
References (official sources; accessed August 24, 2026):
[1] Therapeutic Goods Administration, “Changes to the regulation of vapes” (updated 1 October 2024): https://www.tga.gov.au/products/unapproved-therapeutic-goods/therapeutic-vaping-goods/vaping-hub/changes-regulation-vapes
[2] TGA, “Vapes: information for pharmacists”: https://www.tga.gov.au/products/unapproved-therapeutic-goods/therapeutic-vaping-goods/vaping-hub/vapes-information-pharmacists
[3] TGA, “Product standards: unapproved therapeutic vapes” and linked TGO 110 guidance: https://www.tga.gov.au/products/unapproved-therapeutic-goods/therapeutic-vaping-goods/vaping-hub/product-standards-unapproved-therapeutic-vapes
[4] Federal Register of Legislation, Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021, current compilation: https://www.legislation.gov.au/F2021L00595/latest/text
[5] Australian Department of Health, Disability and Ageing, “About vaping and e-cigarettes”: https://www.health.gov.au/topics/smoking-vaping-and-tobacco/about-vaping
The business scope includes licensed projects: food additive production. General projects: sales of food additives; manufacturing of daily chemical products; sales of daily chemical products; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion; biological feed research and development; industrial enzyme preparation research and development; cosmetics wholesale; domestic trading agency; sales of sanitary products and disposable medical supplies; retail of kitchenware, sanitary ware and daily sundries; sales of daily necessities; food sales (only sales of pre-packaged food).
Copyright ©Guangdong Unique Flavor Co., Ltd.All Rights Reserved. Privacy Policy Return and Exchange Policy
